AzTrials
AzTrials

Lifestyle AlterationKoloPrevNCT07135115

Targeting Lifestyle to Improve Colorectal Cancer Screening

A study testing Digikost report baseline only, Digikost report intensive with individual counselling and webinars and Digikost report intensive in people with Lifestyle Alteration and Tobacco, run by Norwegian Institute of Public Health at 1 site in Norway.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study is to learn whether receiving personalized, digital lifestyle advice during colorectal cancer screening leeds to changes in lifestyle over a two-year follow-up period. Read more about this study

Who is it for?
Ages 55 to 56 years
Conditions the study is for
Lifestyle Alteration, Tobacco, Diet Modification
What is being tested?
Digikost report baseline only, Digikost report intensive with individual counselling and webinars and Digikost report intensive
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16,000 participants
Where
1 siteNorway
Study dates
15 Oct 2025to 31 Dec 2041
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 56 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Invited to the first round of immunochemical faecal blood testing in the national colorectal cancer screening program via a digital platform.

Who cannot join

  • Not invited to the national colorectal cancer screening program.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Paula Berstad, PhD contact

+4793293235

pber@fhi.no

Ane S. Kværner, PhD contact

+4790115747

a.s.kvarner@medisin.uio.no

Norway1 site
  • Norwegian Institute of Public Health

    Oslo, 0379

    Kristin R. Randel, MD, PhD, +4722928889, Kristin.Ranheim.Randel@fhi.no

    Paula Berstad, PhD

Other trials in Norway

About this study

The goal of this study is to learn whether receiving personalized, digital lifestyle advice during colorectal cancer screening leeds to changes in lifestyle over a two-year follow-up period. Changes will be measured using a composite score including diet, alcohol consumption, physical activity, body mass index and smoking habits. The main questions it aims to answer are:

  • Do participants who receive short, personalized digital feedback on their lifestyle - either once or through repeated rounds -change their lifestyle during the two-year study period, compared to those who do not receive any feedback?
  • Does the inclusion of additional contact, such as telephone consultation with healthcare providers, result in further lifestyle changes?
Read more

Researchers will compare three groups which receive digital feedback at different intensities and a control group which does not get any feedback to see if lifestyle changes differ between the groups.

Participants in four different groups will fill in a digital diet and lifestyle questionnaire at the start of the study and 2-4 times after this during the following 2 years.

  • Participants in three of the groups will receive a short digital feedback report on their lifestyle related to health recommendations after each completion of the questionnaire.
  • One of these groups will also be offered to go through the feedback report together with a healthcare provider in a telephone call.
  • This group will also receive invitations to motivational webinars every half year during the 2-year study period. The topics in the webinars address cancer preventive lifestyle.

A secondary goal of the study is to understand whether the invitation to fill in the diet and lifestyle questionnaire affects participation in colorectal cancer screening. Therefore, a fifth group of individuals invited to colorectal cancer screening but not to be invited to fill in the questionnaire will be included for extra comparison. Participation in colorectal cancer screening will be compared between this group and the four groups that are additionally invited to complete the questionnaire.

Another secondary goal is to learn which groups in the society consent to the current study. Therefore, sociodemographic characteristics will be compared between the invited individuals who consent and those who do not consent to the study.

Read the detailed description

This is a five-armed, parallel group randomized controlled trial (RCT) among participants invited to the national colorectal cancer screening programme in Norway (ColorectalScreen Norway). The aim of the trial is to test the effect of intervention with a digital, personally tailored diet and lifestyle feedback (Digikost report) on dietary and lifestyle changes in colorectal cancer screening participants. Additionally, it is an aim to gain knowledge on feasibility and acceptability of the digital diet and lifestyle assessment and feedback at colorectal cancer screening setting.

PRIMARY AIM The main aim is to study the effect of the intervention on 2-year changes in a healthy lifestyle score.

SECONDARY AIMS:

To study:

  • the effect of the intervention on 6-month changes in a healthy lifestyle score
  • whether the effect on changes in the score is dependent on the intensity of the feedback
  • whether introduction of the digital diet and lifestyle questionnaire at ColorectalScreen Norway affects screening participation rate
  • participation rate in the digital diet and lifestyle questionnaire, and sociodemographic participant vs. non-participant characteristics
  • the perceptions and accept of the digital tool in CRC screening participants.
  • feasibility of conducting the study
  • cancer incidence, overall mortality and cancer-specific mortality in this study population until year 2040.

RANDOMIZATION AND THE STUDY ARMS The study will randomize a total of 16,000 individuals invited to ColorectalScreen Norway in a defined time period into the following five arms (1:1:1:1:1): three intervention arms (arm A, B and C), a control arm and an arm not receiving an invitation to the study ("usual care", i.e. usual screening service).

A total of 12,800 colorectal cancer screening invitees will be invited to one of the four trial arms (a control arm and three intervention arms, 3,200 invitees in each arm).

The study arms consist of 19 Hospital Trust strata: Finnmark, Helgeland, Innlandet, Førde, Sørlandet, Telemark, Fonna, Ahus, Bergen, Møre og Romsdal, OUS, Vestre Viken, Østfold, Stavanger, Nordland, Vestfold, UNN, St. Olavs and Nord-Trøndelag. As the randomization in this study is stratified, ColorectalScreen Norway invitees are first divided into strata, and then randomly assigned to one of the five arms. The study has a parallel group design, meaning there are no crossovers between the five arms.

INTERVENTION The intervention in this study is digital individually tailored advice to follow the Norwegian food-based dietary guidelines, including recommendations on physical activity, body weight and avoidance of tobacco.

In the three intervention arms (A, B and C), the participants are asked to complete digital assessment of diet and lifestyle (Digikost questionnaire) at different intensities during the 2-year intervention period.

The digital personalized advice (Digikost report) will be made available and sent automatically to the participant's e-mail immediately after completing the Digikost questionnaire. The intervention will last for up to 2 years, with the number of questionnaire rounds and intensity depending on the study arm. The intensities in the three arms will be:

Intervention arm A: Invitation to complete Digikost questionnaire sent at baseline and after 6 months. The digital advice in the Digikost report will be made available for the participant in an e-mail sent immediately after completion of the Digikost questionnaire at baseline, but not after 6 months.

Intervention arm B: Invitation to complete Digikost questionnaire sent at baseline and after each 6 months through the intervention period, in total four times. The digital advice in the Digikost report will be made available for the participant in an e-mail sent immediately after completion of the Digikost questionnaire.

Intervention arm C: Invitation to complete Digikost questionnaire sent at baseline and after each 6 months through the intervention period, in total four times. The digital advice in the Digikost report will be made available for the participant in an E-mail sent immediately after completion of the Digikost questionnaire. At baseline, the participant will additionally be offered an individual consultation telephone meeting with a healthcare provider, scheduled to take place shortly after the baseline assessment. Information of this offer will be given after completion of the questionnaire. Additionally, the participants will be invited, through e-mail, to inspirational webinars on cancer preventive lifestyle every 6 months, with possibilities for submitting questions prior to the seminar.

The Digikost report will be made available for the participants in the intervention arms A, B and C also after the 2-year Digikost questionnaire at the end of the study period. This, however, is not part of the intervention, but rather a reward for the participants.

COMPARATOR The first comparator (the Control arm) will be invited to complete the digital lifestyle questionnaire at baseline, after 6 months and 2 years, but will not receive any feedback. The second comparator (the "Usual care" arm) is the current standard of practice in ColorectalScreen Norway. The Usual care arm will not receive any questionnaire or feedback.

For one of the secondary aims (sociodemographic participant vs. non-participant characteristics), the group of individuals who complete the questionnaire at baseline will be compared with the group of individuals who do not complete the questionnaire.

ENDPOINTS The primary endpoint, for comparison between Intervention arms A, B and C and Control arm is change in a healthy lifestyle score, which consists of the 2018 WCRF/AICR Score and smoking status. This is defined as difference in the score for each participant assessed at baseline and after the 2-year intervention period. The 2018 WCRF/AICR Score is a point score based on the participant's answers in the Digikost questionnaire. Zero to one point is given for the grade to which the participant complies to each of the seven health recommendations: 1) normal body weight, 2) physical activity, 3) diet rich in wholegrains, vegetables, fruit and beans, 4) limited intake of 'fast foods' and other processed foods high in fat, starches or sugars, 5) limited consumption of red and processed meat, 6) limited consumption of sugar-sweetened drinks, and 7) low alcohol consumption. The 2018 WCRF/AICR Score thus ranges from 0 to 7 points. Added by one score point for smoking status, the healthy lifestyle score will range from 0 to 8 points.

SECONDARY ENDPOINTS

  • change in the healthy lifestyle score after six months (comparison between the Intervention arms A, B and C and Control arm)
  • participation in CRC screening, defined as return of the faecal screening sample at baseline (comparison between the Intervention arms and Control arm, and the Usual care arm)
  • participation in the digital lifestyle questionnaire, that is completing the questionnaire at baseline vs. not completing the questionnaire (comparison between different sociodemographic groups)
  • attendance in the personal consultation telephone meetings and the motivational webinars, and retention rate
  • long-term cancer incidence, total mortality and cancer-specific mortality (comparison between the Intervention arms A, B and C, Control arm and Usual care arm)
  • the acceptability and usefulness of the Digikost tool as perceived by the participants (a qualitative sub-study, described further below).

DATA FROM OTHER SOURCES

  • Statistics Norway data on sociodemographic characteristics (education level, household number, household income, marital status, cohabitation status, immigration status and country of birth). This is to analyse the characteristics of participants vs. non-participants of the Digikost questionnaire.
  • Colorectal cancer screening result at the current and upcoming screening rounds up to five years from invitation to the KoloPrev study, including results from the faecal screening test and colonoscopy findings, drawn from the administrative data system of ColorectalScreen Norway. This is to analyse the intervention effect in more detail, separating between screening participants with 1) positive vs. negative screening test, and 2) precancer and cancer findings, and without screening findings.
  • Cancer Registry data on all cancer incidences until Dec 31, 2040. This is to analyse the intervention effect on the long-term hard endpoints, both by intention-to-treat and per-protocol approach.
  • Cause of Death Registry data until Dec 31, 2040. This is to analyse the intervention effect on the long-term hard endpoints, both by intention-to-treat and per-protocol approach.

THE QUALITATIVE STUDY In order to determine the acceptability of introducing a rapid lifestyle assessment with personalized feedback into the national CRC screening program, the researchers will perform a formative evaluation.

A longitudinal qualitative study will be conducted among a subsample of the intervention group. Individual interviews using semi-structured interview guides will be used to collect the participant's perceptions of the acceptability of completing the Digikost and receiving personalized feedback within the context of the CRC screening, as well as whether they found the feedback motivating. The participants will be followed-up a month after the first interview to collect their motivation and experiences with implementing any lifestyle changes based on the personalized advice.

Being tested
Digikost report baseline only, Digikost report intensive with individual counselling and webinars, Digikost report intensive
Keywords
Lifestyle intervention, Colorectal cancer screening, Diet, Alcohol consumption, Smoking, Body mass index, Physical activity, Digital questionnaire
Medical subject headings
Motor Activity, Alcohol Drinking, Smoking

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Digikost report baseline onlyBehavioural

    The Digikost report will be made available for the participant immediately after completing of the Digikost questionnaire at baseline.

  • Digikost report intensive with individual counselling and webinarsBehavioural

    The Digikost report will be made available for the participant each time after completion of the Digikost questionnaire every 6 months. Additionally, the participant is offered an individual lifestyle counselling meeting by telephone at baseline and invited to inspirational webinars on cancer preventive lifestyle every 6 months.

  • Digikost report intensiveBehavioural

    The Digikost report will be made available for the participant each time after completion of the Digikost questionnaire every 6 months.

Study groups in NCT07135115
Study groupRoleWhat they receive
Lifestyle advice, low intensityExperimentalThe participants will receive digital personally tailored diet and lifestyle advice (the Digikost report) after completion of the Digikost questionnaire at baseline.
Receives: Behavioral: Digikost report baseline only
Lifestyle advice, medium intensityExperimentalThe participants will receive digital personally tailored diet and lifestyle advice (the Digikost report) after completion of the Digikost questionnaire at baseline and after each 6 months through the 2-year intervention period.
Receives: Behavioral: Digikost report intensive
Lifestyle advice, high intensityExperimentalThe participants will receive digital personally tailored diet and lifestyle advice (the Digikost report) after completion of the Digikost questionnaire at baseline and after each 6 months through the 2-year intervention period. Additionally, the participants will be offered an individual telephone counselling meeting on his/her Digikost report with an advisor at baseline, as well as invited to inspirational webinars on cancer preventive lifestyle every 6 months.
Receives: Behavioral: Digikost report intensive with individual counselling and webinars
ControlNo interventionThe participants will be invited to complete the Digikost questionnaire at baseline and after 6 months and 2 years, but will not receive the Digikost report after completing the questionnaire.
Usual careNo interventionParticipants will be treated only with the current standard of practice in ColorectalScreen Norway. Participants will not be informed of the trial, invited to fill in the Digikost questionnaire or receive the Digikost report.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in a healthy lifestyle score

    Difference in a healthy lifestyle score, which consists of the 2018 WCRF/AICR Score added by smoking status for each participant, assessed at baseline and after the 2-year trial period. The healthy lifestyle score is a point score based on the participant's answers in the lifestyle questionnaire. 0-1 point is given for the grade to which the participant complies to each of the eight health recommendations: 1) normal body weight, 2) physical activity, 3) diet rich in wholegrains, vegetables, fruit and beans, 4) limited intake of 'fast foods' and other processed foods high in fat, starches or sugars, 5) limited consumption of red and processed meat, 6) limited consumption of sugar-sweetened drinks, 7) low alcohol consumption and 8) non-smoking. The healthy lifestyle score thus ranges from 0 (worst, meaning no compliance to health recommendations) to 8 points (best, meaning full compliance to health recommendations).

    Measured: From baseline to the end of intervention at 24 months

Secondary outcomes (9)
  1. Participation in colorectal cancer screening

    Return of the faecal screening test sample to the laboratory in ColorectalScreen Norway. Participants receive status 1 if a faecal screening sample is registered at the laboratory, and 0 if a faecal screening sample is not registered at the laboratory.

    Measured: Within 6 months after sending of the faecal screening test kit to the participant at first screening round

  2. Completion of the Digikost questionnaire at baseline

    Participant invited to the trial registers him/herself at the digital study platform and fills in the first round Digikost questionnaire. Participants receive status 1 if completing, and 0 if not completing the questionnaire at baseline.

    Measured: Within 3 months after receiving the invitation to the study

  3. Long-term cancer incidence

    Incidence of any cancer site registered in Cancer Registry after enrollment to the study. The outcome measure includes the ICD code of the diagnosis and the date of diagnosis.

    Measured: From enrollment to the end of follow-up at 16 years

  4. Long-term cancer-specific mortality

    Any cancer site as the death cause registered in Cancer Registry after enrollment to the study. The outcome measure includes the ICD code of the death cause and date of death.

    Measured: From enrollment to the end of follow-up at 16 years

  5. Long-term total mortality

    Death of any cause registered in the Death Cause Registry after enrollment to the study. The measure includes the ICD code of death cause and date of death.

    Measured: From enrollment to the end of follow-up at 16 years

  6. Acceptability

    Acceptability refers to how well the Digikost questionnaire and the intervention will be received by the screening population and the extent to which the intervention is perceived as motivating in the target population. Acceptability will be assessed through qualitative interviews with participants to explore their perceptions with the intervention.

    Measured: Baseline and 1 month

  7. Feasibility of conducting the study, retention

    Feasibility refers to how feasible it is to conduct the study. Feasibility will be assessed by participation rate in the Digikost questionnaire at repated rounds after the baseline. Participants receive status 1 if completing, and 0 if not completing the questionnaire.

    Measured: 6, 12, 18 and 24 months

  8. Feasibility of conducting the study, attendance in the personal consultation telephone meetings

    Feasibility refers to how feasible it is to conduct the study. Feasibility in the "High intensity lifestyle advice" group will be assessed by participation rate in the personal consultation telephone meetings at baseline. Participants receive status 1 if having completed a telephone meeting, and 0 if not having completed a telephone meeting.

    Measured: Baseline

  9. Feasibility of conducting the study, attendance in the motivational webinars

    Feasibility refers to how feasible it is to conduct the study. Feasibility in the "High intensity lifestyle advice" group will be assessed by participation rate in the webinars every 6 months. Participants receive status 1 if having joined a webinar, and 0 if not having not having joined a webinar.

    Measured: 6, 12, 18 and 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2025
  2. Study start15 Oct 2025 (estimated)
  3. Primary completion31 May 2028 (estimated)
  4. Study completion31 Dec 2041 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a five-armed, parallel group and randomized controlled trial. Three of the arms are intervention arms, while two arms are control arms.
Masking
None (open label)
Enrolment
16,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07135115
Sponsor's protocol ID
572721
Other IDs
223165
Acronym
KoloPrev
Status last verified
Aug 2025
First submitted
11 Aug 2025
Last updated
3 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The ethical approval for the data ownership is limited to the study group.

Questions about this trial

What is this clinical trial studying?

A study testing Digikost report baseline only, Digikost report intensive with individual counselling and webinars and Digikost report intensive in people with Lifestyle Alteration and Tobacco, run by Norwegian Institute of Public Health at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 3 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Paula Berstad, PhD (+4793293235, pber@fhi.no), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in a healthy lifestyle score (time frame: From baseline to the end of intervention at 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in